Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS) in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CompoSIT-I
- Sponsors Merck Sharp & Dohme
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 23 Jun 2018 Results from this trial were presented at the 78th Scientific Sessions of the American Diabetes Association (ADA), according to a Merck & Co media release.
- 23 Jun 2018 Results presented in the Merck & Co media release.